Process and Strategies for Patient Engagement and Outreach in the Sickle Cell Disease (SCD) Community to Promote Clinical Trial Participation

Overview

Journal J Natl Med Assoc

Publisher Elsevier

Specialty General Medicine

Date 2022 Jan 30

PMID 35093266

Authors

C Byrnes

M Botello-Harbaum

T Clemons

L Bailey

K M Valdes

V H Coleman-Cowger

Affiliations

Soon will be listed here.

Abstract

Introduction: Sickle cell disease (SCD) is the most common inherited blood disorder in the United States. The Cure Sickle Cell Initiative (CureSCi) was created by the National Heart, Lung and Blood Institute (NHLBI) to improve the lives of people with SCD by accelerating the advancement of safe and promising genetic therapies, engaging the SCD community and healthcare providers, and encouraging collaboration among stakeholders. CureSCi is a collaborative, patient-focused research effort that includes patients at every level of the Initiative. Patient engagement is a key component, particularly during the development of clinical trials.

Objective: To describe the processes and strategies utilized by the CureSCi to engage individuals living with SCD about genetic therapy clinical trials.

Methods: The CureSCi Patient Engagement team conducted nine Community Outreach visits in 2019, each of which was structured to include separate group interviews with patients and medical providers. A set of guidance questions was developed for each audience and the interviews lasted approximately 60 minutes.

Results: Patients were asked about their participation in a clinical trial, and approximately 50% had participated in a trial. SCD individuals reported trusting their medical provider to provide them with information relevant to trials. Medical providers emphasized the individual, family, and health aspects of SCD that warrant additional investigation. Providers reported barriers encountered by patients as transportation, childcare support, infertility, and trust in the healthcare system.

Conclusion: Lessons learned from the community have helped to influence recommendations for clinical trial design and key messaging development for the Cure Sickle Cell Initiative.

References

Puri Singh A, Haywood Jr C, Beach M, Guidera M, Lanzkron S, Valenzuela-Araujo D . Improving Emergency Providers' Attitudes Toward Sickle Cell Patients in Pain. J Pain Symptom Manage. 2015; 51(3):628-32.e3. PMC: 4785055. DOI: 10.1016/j.jpainsymman.2015.11.004. View

Payne A, Mehal J, Chapman C, Haberling D, Richardson L, Bean C . Trends in Sickle Cell Disease-Related Mortality in the United States, 1979 to 2017. Ann Emerg Med. 2020; 76(3S):S28-S36. PMC: 7598427. DOI: 10.1016/j.annemergmed.2020.08.009. View

Benz Jr E, Mondoro T, Gibbons G . Accelerating the Science of SCD Therapies-Is a Cure Possible?. JAMA. 2019; 322(10):921-922. DOI: 10.1001/jama.2019.11419. View

Cho H, Kim S, Fitzhugh C, Hsieh M, Tisdale J, Grady C . Motivations and Decision-Making of Adult Sickle Cell Patients in High-Risk Clinical Research. Biol Blood Marrow Transplant. 2020; 26(6):1225-1232. PMC: 8725975. DOI: 10.1016/j.bbmt.2020.03.014. View

Omondi N, Ferguson S, Majhail N, Denzen E, Buchanan G, Haight A . Barriers to hematopoietic cell transplantation clinical trial participation of african american and black youth with sickle cell disease and their parents. J Pediatr Hematol Oncol. 2013; 35(4):289-98. PMC: 3659415. DOI: 10.1097/MPH.0b013e31828d5e6a. View

Stevens E, Patterson C, Li Y, Smith-Whitley K, Barakat L . Mistrust of Pediatric Sickle Cell Disease Clinical Trials Research. Am J Prev Med. 2016; 51(1 Suppl 1):S78-86. PMC: 4916926. DOI: 10.1016/j.amepre.2016.01.024. View

Lebensburger J, Sidonio R, DeBaun M, Safford M, Howard T, Scarinci I . Exploring barriers and facilitators to clinical trial enrollment in the context of sickle cell anemia and hydroxyurea. Pediatr Blood Cancer. 2013; 60(8):1333-7. PMC: 5319435. DOI: 10.1002/pbc.24486. View

Strong H, Mitchell M, Goldstein-Leever A, Shook L, Malik P, Crosby L . Patient Perspectives on Gene Transfer Therapy for Sickle Cell Disease. Adv Ther. 2017; 34(8):2007-2021. PMC: 6201755. DOI: 10.1007/s12325-017-0587-7. View

Gamble V . Under the shadow of Tuskegee: African Americans and health care. Am J Public Health. 1997; 87(11):1773-8. PMC: 1381160. DOI: 10.2105/ajph.87.11.1773. View

10.

Hassell K . Population estimates of sickle cell disease in the U.S. Am J Prev Med. 2010; 38(4 Suppl):S512-21. DOI: 10.1016/j.amepre.2009.12.022. View

11.

Persaud A, Desine S, Blizinsky K, Bonham V . A CRISPR focus on attitudes and beliefs toward somatic genome editing from stakeholders within the sickle cell disease community. Genet Med. 2018; 21(8):1726-1734. PMC: 6606394. DOI: 10.1038/s41436-018-0409-6. View

12.

Suarez M, Schlaeger J, Angulo V, Shuey D, Carrasco J, Roach K . Keys to Recruiting and Retaining Seriously Ill African Americans With Sickle Cell Disease in Longitudinal Studies: Respectful Engagement and Persistence. Am J Hosp Palliat Care. 2019; 37(2):123-128. PMC: 6933076. DOI: 10.1177/1049909119868657. View